Advances in the development of malaria vaccines

Despite progress in reducing the burden of malaria, achieving global malaria elimination remains challenging. This review explores recent advances and future directions in malaria vaccine development, highlighting the need for new approaches to achieve sustainable protection against Plasmodium species. Early research emphasized the importance of immunogenic antigens and adjuvants to strengthen immune responses, prompting efforts to develop vaccines targeting multiple stages of the parasite's life cycle. Recent initiatives have showcased diverse vaccine candidates in various trial phases, including pre-erythrocytic, blood stage, and transmission blocking vaccines, reflecting an encouraging shift toward more collaborative research. However key challenges persist, particularly in identifying pre-erythrocytic antigens owing to difficulties in obtaining infectious sporozoites and establishing reliable human hepatocyte models. Nevertheless, advances in mass spectrometry, bioinformatics, and structural biology hold promise in filling these gaps. In Africa, where the burden of malaria is the highest, the implementation of the RTS,S/AS01 and R21/Matrix-M vaccines through national Expanded Program on Immunization schedules is under way, underscoring the importance of community engagement and health system readiness while highlighting the need for next generation vaccines with greater durability and breadth. Achieving elimination of malaria requires improving current vaccine strategies, integrating novel technologies, and strengthening delivery mechanisms in endemic regions to overcome both biological and operational barriers.